Clinical Trial Update: Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating sorafenib tosylate with or without everolimus in patients with advanced, radioactive iodine-refractory Hurthle cell thyroid cancer; the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hurthle Cell Thyroid Cancer

Drugs mentioned

• Everolimus (everolimus)
• Sorafenib tosylate (sorafenib tosylate)

Snippet

Sponsor: Alliance for Clinical Trials in Oncology | Conditions: Refractory Hurthle Cell Thyroid Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2022-04-04